We help Support at Home-approved families find care.
Aged Care Home
Support at Home
Retirement Living
Finance & Placement Advice
Healthcare Equipment
Mobility and Equipment
Patient care equipment
Skin and wound Care
Safety and Security
Assessments
Assistive Technology
End of Life
Financial Services
Funerals
Placement Consultants
Advocacy
No results found
No results found
No results found
Advanced Filters
Distance (proximity)
Price Range
RAD (Refundable Accommodation Deposit) is a lump-sum payment for aged care homes. It is fully refundable when the resident leaves, as long as there are no outstanding fees.
Min RAD
Any
$250,000
$500,000
$750,000
$1,000,000
$1,500,000
$1,750,000
$2,000,000
Maximum RAD
Any
$250,000
$500,000
$750,000
$1,000,000
$1,500,000
$1,750,000
$2,000,000
Facility size
Based on how many beds the facilty has.
Any
Small
Medium
Large
Service Delivery
Services offered at a location or in a region
Any
On Site
Service Region
Features
Single rooms with ensuites
Respite beds
Extra service beds
Secure dementia beds
24/7 Registered nursing
Full or Partially government funded
Couples accommodation
Facility has pets
Non-dedicated respite
Palliative care
Partner considered without ACAT
Secure garden
Transition care
Cafe/Kiosk
Chapel/Church
Hairdressing Salon
Facility Owned Transport
Single Rooms
Rooms with ensuites
Registered nursing
Non secure dementia care
Diversional therapy
Medication supervision
Respite care
Secure access
Small pets considered

‘A nose’ on Alzheimer’s disease

A nasal spray is being developed that could transform the early detection and treatment of Alzheimer’s. The device shoots tiny magnetic particles into the nose which enter the bloodstream and are carried to the brain.

Posted
by Grace Mindwell

A nasal spray is being developed that could transform the early detection and treatment of Alzheimer’s.

The device shoots tiny magnetic particles into the nose which enter the bloodstream and are carried to the brain. Each particle is fused to an antibody that targets and binds to rogue molecules believed to play an early role in the disease.

Magnetic resonance imaging (MRI) can detect both the particles and the molecules. Scientists have only tested the technique in the laboratory on human brain tissue cultures.

If it can be shown to work in human patients, it could lead to a major leap forward in managing Alzheimer’s, scientists say.

Scientists believe the changes that lead to Alzheimer’s begin decades before the first symptoms appear.

By the time a patient is diagnosed, the disease is already far advanced, and experts suspect that is the main reason why a number of promising drugs have failed in patient trials. Identifying the disease much earlier could make it far easier to treat.

Lead scientist, William Klein, from Northwestern University, Chicago, said: “We have created a probe that targets a unique marker of Alzheimer’s disease. This technology is a promising tool for early Alzheimer’s diagnosis and for evaluating the efficacy of investigational new drugs at early stages of the disease.”

The scientists are now working on incorporating the particles into a nasal spray.

Read next

Sign up or log in with your phone number
Phone
Enter your phone number to receive a verification notification
Aged Care Guide is endorsed by
COTA logo
ACIA logo